letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...3031323334353637383940...100101»
  • ||||||||||  Piqray (alpelisib) / Novartis
    Journal:  Alpelisib induced interstitial lung disease in a patient with advanced breast cancer. (Pubmed Central) -  Jun 23, 2022   
    Drug-induced interstitial lung disease is usually a diagnosis of exclusion, difficult to identify particularly during the COVID-19 pandemic for patients with cancer. Differential diagnosis includes infectious pneumonia, radiation pneumonitis, diffuse alveolar hemorrhage, pulmonary edema, and pulmonary lymphangitic metastasis.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines. (Pubmed Central) -  Jun 22, 2022   
    Moreover, the PEG-protamine letrozole NPs displayed a strong anticancer action compared to MCF-7 cells with an IC50 70 μM for letrozole and 50 μM for PEG-protamine letrozole NPs. Overall, our results indicate that letrozole PEG-protamine NPs alter the release profile of letrozole, which could be an excellent approach for overcoming letrozole resistance in human breast cancer.
  • ||||||||||  ABSK091 / Abbisko Therap
    P2a data, Clinical Trial,Phase II, Journal:  Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. (Pubmed Central) -  Jun 19, 2022   
    P2a
    Eleven patients had retinal pigment epithelial detachments which was asymptomatic and reversible in all but one patient. Exploratory ribonucleic acid sequencing (RNA-Seq) analysis was done on patients' samples: 6 differentially-expressed-genes could distinguish those who benefited from the addition of AZD4547.
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Retrospective data, Journal:  The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. (Pubmed Central) -  Jun 15, 2022   
    Specifically, OC, MET and CC lead to decreased AMH level, DHEA and VD lead to increased AMH level, and GnRH-a leads to dynamic variation, which is correlated with PCOS, obesity, age, and duration of medication. The impacts of these medications should be taken into consideration when AMH is used as a marker of ovarian reserve.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed, Enrollment change:  Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) -  Jun 9, 2022   
    P2,  N=61, Active, not recruiting, 
    Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023 Recruiting --> Active, not recruiting | N=300 --> 61
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  Hormone Secretion in Transgender Males (clinicaltrials.gov) -  Jun 7, 2022   
    P4,  N=40, Not yet recruiting, 
    This study validates the potential of Fagonia indica for the amelioration of metabolic, as well as, hormonal disturbances that occurred in PCOS. N=26 --> 40 | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Jun 2025 --> Jun 2028
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Biomarker, Journal:  Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. (Pubmed Central) -  Jun 4, 2022   
    The absence of progesterone receptors, presence of liver metastases, and use as second-line or beyond are associated with a reduced median PFS. One year age increase (protective factor), liver metastases (risk factor), response at initial evaluation, and best response achieved are identified as the most predictive factors of the response to this treatment regimen and of the progression risk.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal:  Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy. (Pubmed Central) -  Jun 4, 2022   
    Molecular docking confirmed the capability of these compounds to accommodate into the active site of the enzyme, suggesting that the sustained inhibitory activity of letrozole may be at least in part attributed to the degradation compounds. A structured patient-centered pharmacy practice model integrating the ASCO/NCODA patient-centered standards and ongoing communication with patients and healthcare providers ensure timely refills, close monitoring, and allows patients to achieve high adherence and persistence rates comparable to those reported in clinical trials.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion date:  HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) -  Jun 2, 2022   
    P2,  N=128, Active, not recruiting, 
    A structured patient-centered pharmacy practice model integrating the ASCO/NCODA patient-centered standards and ongoing communication with patients and healthcare providers ensure timely refills, close monitoring, and allows patients to achieve high adherence and persistence rates comparable to those reported in clinical trials. Trial completion date: Jan 2022 --> Jan 2024
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) -  Jun 1, 2022   
    P2,  N=29, Recruiting, 
    Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2023
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  Medical methods for first trimester abortion. (Pubmed Central) -  May 25, 2022   
    Some results are limited by the small numbers of participants on which they are based. Almost all studies were conducted in settings with good access to emergency services, which may limit the generalisability of these results.
  • ||||||||||  letrozole / Generic mfg., exemestane / Generic mfg.
    Journal:  Role of Natural and Synthetic Flavonoids as Potential Aromatase Inhibitors in Breast Cancer: Structure-Activity Relationship Perspective. (Pubmed Central) -  May 25, 2022   
    This essential feature has been utilized to modify several natural flavonoids into 5 and 7 hydroxy/methoxy flavone, 4-imidazolyl/triazolyl flavone, 5,4'- diamino flavone, 7,8- benzo-4-imidazolyl flavone, α-naphthoflavone, and 2-azole/thiazolyl isoflavone derivatives. These scaffolds have been considered in this review for meticulous study in aspects of the structure-activity relationship for aromatase inhibitory activity, and it would likely pave the way for designing a potential lead candidate in the future.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed:  GIM10-CONSENT: CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (clinicaltrials.gov) -  May 24, 2022   
    P3,  N=1000, Active, not recruiting, 
    Trial completion date: Jun 2022 --> Sep 2022 Recruiting --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Aromatase Inhibition Eliminates Sexual Receptivity Without Enhancing Weight Gain in Ovariectomized Marmoset Monkeys. (Pubmed Central) -  May 21, 2022   
    Relative estradiol levels in peripheral serum were E2 >>> VEH > LET, while those in hypothalamus ranked E2 = VEH > LET, confirming inhibition of local hypothalamic estradiol synthesis by letrozole. Our findings provide the first evidence for extra-ovarian estradiol contributing to female sexual behavior in a nonhuman primate, and prompt speculation that extra-ovarian estradiol, and in particular neuroestrogens, may similarly regulate sexual motivation in other primates, including humans.